go-v.orgdoi

The evolving field of post-transplant therapy in multiple myeloma

Sarah A. Holstein, Philip L. McCarthy · Clinical Investigation · 2014

  • DOI 10.4155/cli.14.72
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2014

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2014

Abstract

Multiple myeloma is characterized by monoclonal protein production, immune dysregulation, renal dysfunction and lytic bone disease. The backbone of therapy for patients eligible for high-dose therapy has been induction therapy followed by consolidation with autologous stem cell transplant. The introduction of immunomodulatory drugs and proteasome inhibitors has led to a dramatic improvement in responses to induction therapy, translating to improved survival following transplant. Despite these successes, nearly all patients will eventually relapse. The role of maintenance therapy following transplant to delay recurrence and improve survival continues to be defined.

This review focuses on the most recent clinical trials for maintenance therapy, minimal residual disease detection, the risk of second primary malignancies, as well as future directions in this field.

Open the resolved locator · 10.4155/cli.14.72

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 00:12 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.14.72
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.